← boardnext 2026-07-23next 2026-09next 2026-11next 2028-06-02next 2035-12-31
NVS
Tourmaline Bio, Inc., a Novartis Companydistress 1/10 · well-funded / low risk$152.850%today-9% from 52w high
Neurology 2
Lead: Relapsing Multiple Sclerosis · est. market ~$25B (approx, global)
Revenue
$13524M
Liquidity
$9408M
Runway
—
Shares 1y
0%
Price & events
+8.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
+0.1%
1W
-0.3%
1M
+3.6%
3M
+7.0%
6M
+33.5%
1Y
+51.7%
2Y
+101.3%
5Y
+103.1%
All
Overview
- Market Cap
- $291.66B
- Enterprise Value
- $322.23B
- Volume
- 161.39K
- 52 Week Range
- $114 – $169
- Total Shares
- 1.91B
- Float Shares
- 1.85B
- Short %
- 0.28%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 7.67%
- RVOL
- 0.08x
- Beta
- 0.49
Pipeline stages · 5 programs
Remibrutinib, Teriflunomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TOUR006 - 20 MG, TOUR006 - 50 MG
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CYB704, Ocrevus-EU, Ocrevus-US
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GT005
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Onasemnogene Abeparvovec-xioi
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-23 Estimated 50% readout ~2026-10-06 final ~2027-07-31 | Phase 3 | Remibrutinib, Teriflunomide | Relapsing Multiple Sclerosis | — | active not recruiting |
| 2026-07-23 Estimated 50% readout ~2026-10-06 final ~2027-07-31 | Phase 3 | Remibrutinib, Teriflunomide | Relapsing Multiple Sclerosis | — | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | TOUR006 - 20 MG, TOUR006 - 50 MG | Thyroid Eye Disease | — | active not recruiting |
| 2026-11 Estimated 50% readout ~2027-01-15 | Phase 3 | CYB704, Ocrevus-EU, Ocrevus-US | Relapsing Multiple Sclerosis | — | active not recruiting |
| 2028-06-02 Estimated 50% readout ~2028-07-17 | Phase 2 | GT005 | Age Related Macular Degeneration (AMD) | — | enrolling by invitation |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2035-12-31 Estimated 50% readout ~2036-03-15 | Phase 3 | Onasemnogene Abeparvovec-xioi | Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-07-21Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,908,151,679 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $155 (+1% upside) · 10 analysts
- 2026-03-26Morgan StanleyOverweight
- 2026-01-06BarclaysUnderweight → Equal-Weight
- 2025-12-08JP MorganNeutral → Overweight
- 2025-09-12Goldman SachsNeutral → Sell
- 2025-02-13UBSBuy → Neutral
- 2024-11-19Erste GroupBuy → Hold
Competitors — Relapsing Multiple Sclerosis
Recent news
- 2026-07-23NOVARTIS AG : Jefferies gives a Neutral rating - marketscreener.com
- 2026-07-23Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline - Yahoo Finance
- 2026-07-22Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline - Sahm
- 2026-07-22NOVARTIS AG : DZ Bank sticks Neutral - marketscreener.com
- 2026-07-22Novartis Stock: The Buy Thesis Is Back (Rating Upgrade) (NYSE:NVS) - Seeking Alpha
- 2026-07-22NOVARTIS AG : Bernstein reaffirms its Neutral rating - marketscreener.com
- 2026-07-22NOVARTIS AG : Deutsche Bank maintains a Buy rating - marketscreener.com
- 2026-07-22NOVARTIS AG : UBS is Neutral - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.